Ipamorelin: Research Overview, Mechanisms, and Current Evidence
Ipamorelin is a synthetic pentapeptide that acts as a growth hormone secretagogue, binding the ghrelin receptor (GHSR-1a) to stimulate release of growth hormone from the pituitary. It has been studied in preclinical research as a selective growth hormone releaser and as a ghrelin-mimetic, but it is not an approved drug. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
In preclinical models, ipamorelin has been characterized as a selective ghrelin receptor agonist that stimulates growth hormone release.
- Binds the growth hormone secretagogue receptor (ghrelin receptor, GHSR-1a) on pituitary cells.
- Reported to stimulate growth hormone release with selectivity, with limited effect on cortisol and prolactin in early studies.
- Studied as a ghrelin-mimetic for effects on appetite signaling and gut motility in animal models.
- Investigated for effects on body weight in models of treatment-induced weight loss.
Areas of Research Interest
Published studies have examined ipamorelin in the following research contexts. The evidence is largely preclinical, with limited clinical data.
Growth hormone release
Studied as a selective growth hormone secretagogue acting through the ghrelin receptor.
Weight loss and appetite
Investigated in animal models for effects on weight loss associated with chemotherapy.
Gut motility
Examined as a ghrelin-mimetic for effects on gastrointestinal contractions.
Receptor imaging
Used in chemistry research as a template for ghrelin receptor imaging probes.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Animal-study doses are expressed per kilogram of body weight.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Cisplatin-induced weight loss (ferret model) | 1 to 3 mg/kg, intraperitoneal, every 24 hours | Lu 2024·DOI |
| Ghrelin receptor pharmacology (in vitro) | Studied as a peptidomimetic ghrelin receptor ligand in cell-based binding assays | Fowkes 2018·DOI |
| Human research | A growth hormone secretagogue that is not an approved drug; reviews describe limited clinical evidence and poorly defined long-term risks | Coutinho 2026·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2006 to 2026)
Peer-reviewed literature indexed on PubMed characterizes ipamorelin as a ghrelin receptor agonist in preclinical and pharmacology research, alongside reviews that caution about its unregulated use.
Peptides in sport (critical review)
A 2026 critical review of peptide and peptide-analog drugs in sport listed ipamorelin among growth hormone secretagogues promoted for muscle growth and recovery, while emphasizing limited clinical evidence and potential risks such as cardiovascular strain and insulin resistance. PubMed·DOI
Chemotherapy-related weight loss (ferret)
A 2024 study reported that ipamorelin at 1 to 3 mg/kg inhibited cisplatin-induced weight loss during the delayed phase in ferrets by about 24 percent, though it did not reduce the associated vomiting. PubMed·DOI
Ghrelin receptor imaging chemistry
A 2018 study used ipamorelin among growth hormone secretagogue templates while developing fluorine-18 probes to image the ghrelin receptor, which is overexpressed in some cancers and heart failure. PubMed·DOI
Ghrelin system biology
A 2006 study reported that administering ipamorelin to fish enhanced expression of the ghrelin gene, illustrating the peptide's use as a tool for probing the growth hormone secretagogue system. PubMed·DOI
Research Questions
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor to stimulate growth hormone release, studied as a selective growth hormone secretagogue.
What is the current state of human evidence?
The evidence is largely preclinical. Ipamorelin is not an approved drug, and reviews describe the clinical evidence for its use as limited.
What does the available safety literature suggest?
Reviews of peptide use in sport flag potential risks such as cardiovascular strain and insulin resistance, especially with unregulated products and supraphysiological dosing. Long-term human safety has not been established.
Referenced Citations
Literature indexed on PubMed.
- Coutinho, L.F.D., et al. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J. Sports Med. Phys. Fitness, 66(7), 880-885. PubMed·DOI
- Lu, Z., et al. (2024). The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiol. Behav., 284, 114644. PubMed·DOI
- Fowkes, M.M., et al. (2018). Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. Eur. J. Med. Chem., 157, 1500-1511. PubMed·DOI
- Yeung, C.M., et al. (2006). Seabream ghrelin: cDNA cloning, genomic organization and promoter studies. J. Endocrinol., 189(2), 365-379. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.